Phase 2 Clinical Trial of GH001 in Postpartum Depression

NCT05804708 PHASE2 TERMINATED

This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 female participants with clinically diagnosed postpartum depression (PPD) will be included in this study. The participants will receive an individualized dosing regimen (IDR) with at least one and up to three doses of GH001 administered within a single day.

Details

Lead sponsor	GH Research Ireland Limited
Phase	PHASE2
Status	TERMINATED
Enrolment	10
Start date	Thu Mar 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Nov 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Postpartum Depression
• Postnatal Depression

Interventions

• GH001

Countries

United Kingdom, Netherlands